Our Current Clinical Research Studies
Hyperuricemic subjects with Gout and Mild to moderate Chronic Kidney Disease
Patients with Diabetic Cardiomyopathy
Outpatients with Mild to Moderate Covid-19 Illness
Participants with Atherosclerotic Cardiovascular Disease who are not adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
Patients with Chronic Heart Failure with Reduced Ejection Fraction
Patients with Diabetic Cardiomyopathy
Patients with Heart Failure with Preserved Ejection Fraction Acute decompensated Heart Failure who have been stabilized during hospitalization
Adaptive Platform treatment trial for Outpatients with Covid-19
A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients with COVID-19 with Gastrointestinal Infection
Rivus Pharmaceuticals, KBP Bioscience, AstraZeneca, Gilead Sciences.
Rivus Pharmaceuticals
Exploratory Phase 2A, Double-Blind, Placebo-Controlled Study of Subjects with Obese Heart Failure with Preserved Ejection Fraction.
KBP Biosciences
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage 3b/4) Chronic Kidney Disease.
AstraZeneca AB
A Phase 2, Randomised, Double-Blind, Placebo in Adults with Moderate-to-Severe Uncontrolled Asthma
Gilead Sciences
A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)